Evaluation of Effectiveness of Two Different Doses of Mivacurium in Rapid Sequence Intubation (RSI)

Al-Azhar University

Status: Enrolling

Conditions: Emergencies

Treatments: Drug: "Mivacurium Chloride"

Study type: Interventional

Funder types: Other

Identifiers

NCT06072534

mivacurium in RSI

Details and patient eligibility

About

Mivacurium can be considered as an optimal choice for muscle relaxation in short duration surgeries, as butyrylcholinesterase can rapidly and reliably degrade this benzylisoquinoline muscle relaxant in vivo. However the histamine release related to a rapid high-dose injection, unsatisfactory intubation conditions and unexpected delay in recovery in patients may be encountered with butyrylcholinesterase deficiency

Full description

Intubation in emergency and full stomach patients stands as a challenge in anaesthesia. Rapid sequence induction (RSI) is the key player technique in avoiding gastric contents aspiration risk. Non-depolarizing neuromuscular blocking agents as mivacurium are of clinical significance in the anesthetic management of patient. Mivacurium has been has been preferred in situations who necessitating hemodynamic solidity all over the surgery, as only transient tachycardia and hypotension were recorded

Aim of work Using high doses of mivacurium can provide accepted condition of emergency intubation within favorable time - monitoring hemodynamics changes during and after intubation, time of recovery from high doses of muscle relaxant

Enrollment: 100 estimated patients

Sex: All

Ages: 20 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 20-60 year old patients.
• American society of anaesthesia (ASA) 1 and 2.
• Emergency surgery.

Exclusion criteria

• Refusal.
• allergy.
• neuromuscular disease.
• Suspected desaturation.
• Severe cardiac disease.
• Severe pulmonary disease.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups

Miva 3

Active Comparator group

Description:

"Mivacurium chloride" ("Mivacron®") 0.3 mg/kg 3 times effective dose (ED) 95 iv during induction recording intubation condition during rapid sequence intubation within 90 sc monitoring hemodynamic changes during intubation ,time to recover to T1

Treatment:

Drug: "Mivacurium Chloride"

Miva 4

Active Comparator group

Description:

"Mivacurium chloride" ("Mivacron®") 0.4 mg/kg 4 times effective dose (ED) 95 iv during induction recording intubation condition during rapid sequence intubation within 90 sc monitoring hemodynamic changes during intubation,time to recover to T1

Treatment:

Drug: "Mivacurium Chloride"